Does Medicare Cover Zepbound for Sleep Apnea? The Part D Picture

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 11 sources cited · Author: FormBlends Editorial

Key Takeaways

• Some Medicare Part D plans began covering Zepbound for OSA after the December 2024 FDA approval; coverage is uneven across plans
• CMS guidance in early 2025 recognized OSA as a Part D-coverable indication, distinct from the weight-loss exclusion that historically blocked Medicare coverage of obesity medications
• Prior authorization requirements mirror commercial plans: AHI 15+, BMI 30+, clinical documentation of the FDA OSA indication
• The 2025 Part D out-of-pocket cap of $2,000 annually limits maximum exposure but most Zepbound patients still hit the cap early in the year
• Medicare Advantage plans must match Part D minimums; many added OSA coverage in 2025 formulary cycles

Direct answer

Medicare Part D coverage of Zepbound for moderate-to-severe obstructive sleep apnea make availableed partially after the December 2024 FDA approval. CMS issued guidance in early 2025 distinguishing the OSA indication from the historical weight-loss exclusion, opening a Part D coverage path. Plan implementation has been uneven; some Part D plans added the indication during 2025 formulary updates, others did not. Coverage requires prior authorization documenting AHI 15+, BMI 30+, and the FDA OSA indication. Out-of-pocket costs are capped at $2,000 annually under the 2025 Part D reforms.

Table of contents

1. Why Medicare's position is structurally different
2. The weight-loss exclusion and how OSA bypasses it
3. CMS guidance and the 2025 coverage shift
4. How to check your specific Part D plan
5. Prior authorization on Medicare
6. The 2025 Part D out-of-pocket cap
7. Medicare Advantage versus standalone Part D
8. Mounjaro versus Zepbound on Medicare
9. The Medicare appeals process
10. Decision framework
11. FAQ
12. Sources

Why Medicare's position is structurally different

Commercial insurance plans make coverage decisions based on FDA indications, plan formularies, and prior authorization criteria. Medicare's structure has additional constraints written into the underlying statutes.

The most important: the Medicare Modernization Act of 2003 explicitly excluded "agents when used for anorexia, weight loss, or weight gain" from Medicare Part D coverage. This was the operative provision that blocked Medicare from covering Wegovy, Saxenda, and other obesity medications.

The exclusion was based on a historical concern about appetite-suppressant drugs (fen-phen and earlier agents) that had safety problems. It predated the modern GLP-1 era. The statute has not been amended despite multiple legislative attempts.

The way around the exclusion: a medication is eligible for Part D coverage if used for a condition that is itself coverable. Weight loss as an end is excluded. But treatment of conditions for which the drug is FDA-approved is generally coverable, even when the underlying mechanism involves weight loss.

This is the regulatory backbone for Medicare coverage of:

• Ozempic for type 2 diabetes (covered)
• Wegovy for cardiovascular risk reduction in CVD patients (covered as of 2024 indication expansion)
• Zepbound for moderate-to-severe OSA in obesity (covered, with implementation variation)

And the reason these are not covered:

• Wegovy for obesity alone, in patients without CVD (excluded under the weight-loss provision)
• Zepbound for obesity alone, in patients without OSA (excluded)

The weight-loss exclusion and how OSA bypasses it

The December 2024 Zepbound OSA approval gave Eli Lilly a regulatory hook for Medicare coverage. The argument: OSA is a specific medical condition, not weight loss. Tirzepatide treats OSA according to its FDA label. Therefore, Part D coverage should apply, the weight-loss exclusion notwithstanding.

CMS broadly accepted this argument in 2025 guidance. The agency clarified that medications approved for specific medical indications can be covered under Part D when used for those indications, even when the medication is also used for weight loss in other contexts.

The practical implication: Zepbound coverage on Medicare depends on the diagnosis attached to the prescription. With an OSA diagnosis code (G47.33) and appropriate documentation, the prescription is potentially coverable. With an obesity diagnosis code (E66.x) alone, the prescription falls under the weight-loss exclusion.

This creates a strong incentive for accurate diagnosis coding. Patients with both OSA and obesity should ensure the OSA diagnosis is the primary code submitted for the prescription, not just listed as a comorbidity.

CMS guidance and the 2025 coverage shift

CMS issued written guidance in early 2025 (specifically through Part D rulemaking and clarifying memos) addressing the Zepbound OSA coverage question. Key elements:

• OSA is a medically accepted indication under Part D rules
• Plans may cover Zepbound for OSA; plans may apply prior authorization criteria aligned with the FDA indication
• Plans are not required to cover Zepbound for OSA; coverage is at plan discretion subject to formulary rules
• The weight-loss exclusion does not bar OSA coverage, but does continue to bar obesity-only coverage

The "may cover, not must cover" framing produced uneven plan responses. Some Part D plans embraced the new indication and added Zepbound during 2025 formulary cycles. Others continued to exclude Zepbound entirely, citing cost or other factors.

As of May 2026, approximate patterns:

• ~40-50% of standalone Part D plans cover Zepbound for OSA with prior authorization
• ~50-60% of Medicare Advantage prescription benefits cover it
• Coverage is more common in higher-premium plans
• Some plans cover but with very strict prior authorization criteria that limit practical access

How to check your specific Part D plan

The most direct path is the Medicare.gov Plan Finder tool. Steps:

1. Go to medicare.gov/plan-compare
2. Enter your ZIP code and Medicare plan type (Part D or Medicare Advantage)
3. Add "Zepbound" to your medication list
4. The tool will show which plans in your area cover Zepbound and at what tier
5. Plans showing Zepbound on formulary with prior authorization typically include OSA as the covered indication; verify directly with the plan

Alternative paths:

• Call your Part D plan's member services line and ask specifically about Zepbound for OSA
• Check the plan's online formulary document (usually a PDF on the plan website)
• Ask your prescriber's office to verify coverage before submitting a prescription

Some plans publish OSA-specific prior authorization criteria as a separate document from the standard formulary. The plan's pharmacy benefit manager (PBM) often publishes more detail than the plan's consumer-facing materials.

Prior authorization on Medicare

Standard Medicare Part D prior authorization for Zepbound-OSA typically requires:

Element	Typical requirement
OSA diagnosis	Polysomnography or home sleep test with AHI 15+
Sleep study recency	Within last 2-5 years
BMI	30 or higher
Age	18 or older
PAP history	Some plans require attempt or intolerance; many do not
Diagnosis code on claim	G47.33 (obstructive sleep apnea); E66.x as supporting code
Reauthorization	6-12 months typically; documented weight loss and/or AHI improvement

Medicare prior authorization is generally not faster than commercial plan prior authorization. Standard processing is 7-14 days. Expedited review (24-72 hours) is available when delay would harm health, but the bar for expedition is generally high.

The 2025 Part D out-of-pocket cap

The Inflation Reduction Act introduced a cap on Medicare Part D out-of-pocket spending starting January 2025. The cap is $2,000 annually across all covered Part D medications.

For Zepbound patients on Medicare:

• Zepbound retail is approximately $1,050 per month for the auto-injector
• Without coupons (which government insurance patients cannot use), Medicare patients are responsible for the cost-sharing structure of their plan (deductible, coinsurance, copay)
• Most patients hit the $2,000 cap within 2-4 months of starting Zepbound
• After the cap, the remainder of the year is at $0 out-of-pocket for that medication and any other covered Part D medications

The cap is a meaningful financial protection. Pre-2025, Medicare patients on Zepbound could face thousands per month indefinitely. Post-2025, the worst-case is $2,000 for the entire year of Part D spending.

The cap does not apply to:

• Drugs not covered by Part D (uncovered medications)
• Drugs that fall under Part B (administered by providers)
• Compounded medications obtained outside Part D

Medicare Advantage versus standalone Part D

Medicare beneficiaries get prescription drug coverage through one of two paths:

• Standalone Part D plan paired with traditional Medicare
• Medicare Advantage (Part C) with prescription benefit, sometimes called MA-PD

Both must offer at least the coverage required by Part D rules, including the same drug categories and the $2,000 annual cap as of 2025. Each plan can structure its formulary differently within those minimums.

Patterns for Zepbound-OSA coverage:

• Medicare Advantage plans were generally faster to add Zepbound-OSA than standalone Part D plans, possibly because MA plans have stronger incentives to attract beneficiaries with specific coverage needs
• Higher-premium MA plans tend to have broader coverage
• Some MA plans use step therapy (try other medications first) for Zepbound-OSA; this is less common in standalone Part D

If you are considering switching Medicare plans during the Annual Election Period (Oct 15 to Dec 7) or the Medicare Advantage Open Enrollment Period (Jan 1 to Mar 31), Zepbound coverage can be a meaningful factor in plan selection.

Mounjaro versus Zepbound on Medicare

Mounjaro and Zepbound are the same molecule (tirzepatide), different brand names with different FDA indications:

• Mounjaro: Approved for type 2 diabetes. Covered by Medicare Part D for diabetes.
• Zepbound: Approved for obesity (and now OSA). Coverage was previously blocked by the weight-loss exclusion; OSA approval opened a Part D path.

For Medicare patients with OSA and type 2 diabetes:

• Mounjaro is covered under the diabetes indication and is usually the simpler path
• The OSA benefit accrues alongside diabetes treatment
• Zepbound is not necessary if Mounjaro is providing the same molecule under a more established indication

For Medicare patients with OSA but without diabetes:

• Zepbound is the path; Mounjaro is not on-label for OSA
• Coverage depends on the specific Part D plan's adoption of the OSA indication

The Medicare appeals process

Medicare prescription drug appeals run through five levels:

1. Redetermination by the plan. Written request, processed within 7 days (or 72 hours expedited). Most denials are first appealed here.
2. Reconsideration by Independent Review Entity (IRE). If redetermination is unfavorable, the IRE reviews independently of the plan. Processed within 7 days standard.
3. Administrative Law Judge (ALJ) hearing. Available when the amount in dispute exceeds a threshold (approximately $190 in 2026). Hearings are conducted by Office of Medicare Hearings and Appeals.
4. Medicare Appeals Council review. Available after ALJ decision.
5. Federal court review. Final option, with a higher amount-in-controversy threshold.

Most Zepbound-OSA disputes resolve at level 1 or 2. The documentation that helps:

• Full sleep study report with AHI 15+ clearly stated
• BMI documentation showing 30+
• Clinical note specifically referencing the FDA OSA indication and the December 2024 approval
• If applicable, CPAP history and adherence data
• For higher-level appeals, professional society guidance and the FDA label as supporting evidence

Decision framework

If you have OSA and type 2 diabetes on Medicare: Mounjaro is the simpler path. The OSA benefit accrues alongside diabetes treatment.

If you have OSA without diabetes on Medicare: Check whether your Part D plan covers Zepbound. If yes, prior authorization with appropriate documentation usually approves. If no, consider switching plans at the next enrollment period or pursue an appeal.

If you have OSA on Medicare and your plan denies Zepbound: Appeal. Level 1 redetermination first; level 2 IRE if needed. Document AHI, BMI, and FDA indication carefully.

If you have OSA on Medicare and your plan does not list Zepbound: Switching plans during the Annual Election Period (Oct 15 to Dec 7) is the cleanest fix. Compare Part D plans on Medicare.gov Plan Finder.

If you have OSA on Medicare and cannot afford Zepbound: The $2,000 Part D out-of-pocket cap (effective January 2025) limits annual exposure. Extra Help (Low-Income Subsidy) reduces costs further for income-eligible patients. Eli Lilly's patient assistance programs may apply in some cases.

If you're on Medicare Advantage with OSA: Same general logic as Part D, with attention to step therapy requirements that some MA plans use.

Compounded medication note for this topic

For Does Medicare Cover Zepbound for Sleep Apnea? The Part D Picture, keep the pharmacy distinction clear: when compounded semaglutide or tirzepatide is prescribed, it is prepared for an individual patient by a licensed 503A compounding pharmacy. Compounded preparations are not FDA-approved drug products and are not interchangeable with Ozempic, Wegovy, Mounjaro, or Zepbound.

The practical question is not whether a compounded medication is a brand substitute. It is whether the prescription, pharmacy label, concentration, follow-up plan, and adverse-event support are clear enough for your specific medical history.

FAQ

Does Medicare cover Zepbound for sleep apnea? Some Part D plans do, with prior authorization. Coverage is not universal. CMS guidance in 2025 established that the OSA indication can be covered, but plans implement that guidance unevenly.

Why is Medicare coverage so complicated? The Medicare Modernization Act of 2003 excludes weight-loss medications from Part D. The OSA indication is medically accepted and not weight loss specifically, which provides a coverage path, but plans implement the distinction unevenly.

How do I find out if my plan covers it? Check Medicare.gov Plan Finder, your plan's formulary, or call member services. Verify both that Zepbound is listed and that the OSA indication is recognized.

What does prior authorization require? Sleep study with AHI 15+, BMI 30+, age 18+, and clinical documentation of the FDA OSA indication.

What if my Part D plan denies? Five-level Medicare appeals process. Most denials resolve at level 1 (plan redetermination) or level 2 (IRE).

Does Medicare Advantage work the same way? Must meet Part D minimums. Many MA plans were faster to add Zepbound-OSA coverage. Some use step therapy.

What about Mounjaro for OSA on Medicare? Mounjaro is approved for diabetes only. Medicare covers Mounjaro for diabetes; OSA benefit accrues alongside. For OSA without diabetes, Zepbound is the path.

Will the cost be manageable? The 2025 Part D out-of-pocket cap is $2,000 annually. Most Zepbound patients hit the cap within 2-4 months. Extra Help reduces costs for low-income beneficiaries.

Can I use a manufacturer coupon on Medicare? No. Eli Lilly's savings cards are not available to Medicare, Medicaid, or TRICARE patients.

What about Wegovy on Medicare? Wegovy is covered for cardiovascular risk reduction in patients with established CVD and overweight/obesity (per the 2024 indication expansion). Not covered for obesity alone or OSA.

How long does prior authorization take? Standard 7-14 days. Expedited (24-72 hours) available when delay would harm health.

Should I switch plans at enrollment? If your current plan does not cover Zepbound and another available plan does, switching during the Annual Election Period (Oct 15 to Dec 7) is reasonable. Compare comprehensively, including total cost of all your medications.

Sources

1. Malhotra A et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA). NEJM. 2024.
2. FDA Drug Label. Zepbound (tirzepatide) Prescribing Information. Updated December 2024 to include OSA indication.
3. Centers for Medicare and Medicaid Services. Part D Coverage Guidance. 2025.
4. Medicare Modernization Act of 2003, Section 1860D-2(e)(2).
5. Inflation Reduction Act of 2022. Part D out-of-pocket cap provisions.
6. Office of Medicare Hearings and Appeals. Procedures for Part D Appeals. 2024-2025.
7. Medicare.gov. Plan Finder Tool. Accessed May 2026.
8. Eli Lilly. Zepbound Patient Assistance Program. 2024-2026.
9. CMS. Annual Notice of Changes for Medicare Part D Plans. 2025-2026.
10. American Academy of Sleep Medicine. Clinical Practice Guideline for the Treatment of Adult OSA. 2019.
11. ICD-10-CM Official Guidelines for Coding and Reporting. FY 2026.

Footer disclaimers

Platform Disclaimer. FormBlends provides educational information about Medicare coverage of GLP-1 medications. We are not a Medicare plan or Medicare counselor. For personalized Medicare advice, contact 1-800-MEDICARE or a State Health Insurance Assistance Program (SHIP) counselor.

Compounded Medication Notice. Compounded tirzepatide is not FDA-approved for any indication and has not been studied for OSA. Compounded medications obtained outside Part D do not count toward the $2,000 out-of-pocket cap. Compounded preparations are not interchangeable with brand-name Zepbound or Mounjaro.

Results Disclaimer. Medicare Part D coverage varies by plan, year, and state. Approval criteria and formulary placement change with annual plan updates. Statements about coverage percentages and patterns reflect best information available as of May 2026.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Medicare and Medicare Advantage are programs of the U.S. Department of Health and Human Services. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies or government programs.